Health Economics
Cross-source consensus on Health Economics from 1 sources and 6 claims.
1 sources · 6 claims
Uses
Comparisons
Highlighted claims
- The economic evaluation is conducted from the NHS perspective. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- The consented subsample provides EQ-5D-5L quality-of-life data at baseline and 90 days post-discharge. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- Primary health economic analysis is based on cost-effectiveness for readmissions within 90 days. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- If CHARMER is both less expensive and more effective than usual care, it is considered to dominate usual care. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- A long-term health economic model will explore longer-term prescribing costs and mortality. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial
- The evaluation includes resources needed to deliver CHARMER, including workshops, video viewing, briefings, action-plan preparation, and benchmarking reports. — Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial